Oncolytics Biotech Inc.
ONCYOncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses.
Drugs in Pipeline
6
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
REOLYSIN
Metastatic or Recurrent Squamous Cell Carcinoma of the Lung
Carboplatin
Carcinoma, Squamous Cell of the Head and Neck
Pelareorep
Anal Cancer Metastatic
REOLYSIN®
Carcinoma, Non-small Cell Lung
Paclitaxel
Metastatic Melanoma
Gemcitabine
Metastatic Pancreatic Adenocarcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
REOLYSIN | Phase 3 | Metastatic or Recurrent Squamous Cell Carcinoma of the Lung | - | - |
Carboplatin | Phase 3 | Carcinoma, Squamous Cell of the Head and Neck | - | - |
Pelareorep | Phase 2 | Anal Cancer Metastatic | - | - |
REOLYSIN® | Phase 2 | Carcinoma, Non-small Cell Lung | - | - |
Paclitaxel | Phase 2 | Metastatic Melanoma | - | - |
Gemcitabine | Phase 2 | Metastatic Pancreatic Adenocarcinoma | - | - |